Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $656.00 MXN
Change Today +1.30 / 0.20%
Volume 115.0
GSKN On Other Exchanges
As of 4:09 PM 10/2/15 All times are local (Market data is delayed by at least 15 minutes).

glaxosmithkline plc-spon adr (GSKN) Snapshot

Previous Close
Day High
Day Low
52 Week High
04/15/15 - $741.50
52 Week Low
10/15/14 - $581.90
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

glaxosmithkline plc-spon adr (GSKN) Details

GlaxoSmithKline plc creates, discovers, develops, manufactures, and markets pharmaceutical products, including vaccines, over-the-counter medicines, and health-related consumer products worldwide. The company offers pharmaceutical products in the therapeutic areas, including respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, and emesis, dermatology, rare diseases, immuno-inflammation, vaccines, and HIV. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health areas. The company’s wellness products include Panadol and Panadol Cold & Flu for headache, joint pain, fever, and cold symptoms; ENO and Tums that are immediate relief antacids; and Nicorette (US), Nicoderm, NiQuitin CQ, and Nicabate for the treatment of nicotine withdrawal as an aid to smoking reduction and cessation. Its oral health products comprise Sensodyne to treat and prevent dental sensitivity and acid erosion; Polident, Poligrip, and Corega to enhance comfort of fitted dentures and to clean dentures; and Aquafresh for the prevention of caries, gum disease, and bad breath. The company’s nutrition products include Horlicks, a nutritional beverages and food; and skin health products comprise Physiogel, a face and body care product for dry, sensitive, and irritated skin, as well as Zovirax and Abreva to treat and prevent the onset of cold sores. GlaxoSmithKline plc was founded in 1935 and is headquartered in Brentford, the United Kingdom.

97,921 Employees
Last Reported Date: 02/26/15
Founded in 1935

glaxosmithkline plc-spon adr (GSKN) Top Compensated Officers

Chief Executive Officer, Executive Director, ...
Total Annual Compensation: 2.0M GBP
Chief Financial Officer, Executive Director, ...
Total Annual Compensation: 1.2M GBP
Chairman of Global Vaccines, Executive Direct...
Total Annual Compensation: $2.3M
Compensation as of Fiscal Year 2014.

glaxosmithkline plc-spon adr (GSKN) Key Developments

GlaxoSmithKline Invests USD 11 Million at Facility in Buenos Aires, Argentina

GlaxoSmithKline announced the expansion of its production plant in San Fernando, in Buenos Aires province, to produce Corega Cream, reports Pharmabiz. The company has invested USD 11 million to generate a local production capacity of 30 million tubes per year, allowing for the supply to both the local market and to other regional markets such as Bolivia, Brazil, Chile, Colombia, Ecuador, Paraguay, Peru, Uruguay, and Venezuela.

GSK Reportedly Puts Parkway West Office Campus On Block

GlaxoSmithKline plc (LSE:GSK) (GSK) is planning to sell assets. The company has formally put its office campus on the Parkway West on the market. According to the news report, Jones Lang LaSalle is marketing the property for sale. According to the report, Dan Adamski, Managing Director of the Pittsburgh office of JLL declined to comment. It further added that in an email, Joanmarie Goddard, a spokeswoman GSK said that Pittsburgh officewill be consolidated into a new office in Warren.

GSK Receives Approval for ARNUITY™ ELLIPTA® (Fluticasone Furoate) in Canada for the Treatment of Asthma

GSK announced that ARNUITY ELLIPTA (fluticasone furoate dry powder for oral inhalation) has been approved in Canada as a once-daily inhaled corticosteroid (ICS) medicine for maintenance treatment of steroid-responsive bronchial asthma in patients aged 12 years and older. The approved strengths are ARNUITY ELLIPTA 100 mcg and 200 mcg. ARNUITY is administered once daily via the dry powder inhaler called ELLIPTA, which is also used across a range of other approved respiratory medicines in the GSK portfolio.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GSKN:MM $656.00 MXN +1.30

GSKN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
3M Co $143.20 USD +2.40
AbbVie Inc $55.82 USD +0.69
Celgene Corp $116.44 USD +3.58
Eli Lilly & Co $87.52 USD +2.34
Medtronic PLC $71.13 USD +2.73
View Industry Companies

Industry Analysis


Industry Average

Valuation GSKN Industry Range
Price/Earnings 6.2x
Price/Sales 2.6x
Price/Book 8.8x
Price/Cash Flow 6.2x
TEV/Sales 2.6x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GLAXOSMITHKLINE PLC-SPON ADR, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at